Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75911
UPID:
DHRS3_HUMAN
Alternative names:
DD83.1; Retinal short-chain dehydrogenase/reductase 1; Retinol dehydrogenase 17; Short chain dehydrogenase/reductase family 16C member 1
Alternative UPACC:
O75911; B2R7F3; Q5VUY3; Q6UY38; Q9BUC8
Background:
Short-chain dehydrogenase/reductase 3, known by alternative names such as DD83.1, Retinal short-chain dehydrogenase/reductase 1, Retinol dehydrogenase 17, and Short chain dehydrogenase/reductase family 16C member 1, plays a crucial role in the visual cycle. It catalyzes the reduction of all-trans-retinal to all-trans-retinol in the presence of NADPH, a key step in the regeneration of the visual pigment rhodopsin.
Therapeutic significance:
Understanding the role of Short-chain dehydrogenase/reductase 3 could open doors to potential therapeutic strategies.